Results 131 to 140 of about 1,043 (146)

Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection

Antiviral Research, 2019
Sunwen Chou, Jingyang Wu
exaly  

Foscarnet/ganciclovir/maribavir

Reactions Weekly, 2013
openaire   +1 more source

Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir

Clinical Infectious Diseases
Martha Fournier, Jingyang Wu, Dominik Selleslag   +2 more
exaly  

Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review

Journal of Clinical Virology, 2017
Mark Gompels, Matthew Donati, Sarah Johnston   +2 more
exaly  

In vitro metabolic and transporter profiling for maribavir (SHP620)

Drug Metabolism and Pharmacokinetics, 2019
Devin Welty, Kefeng Sun, Haojing Rong, Ivy Song   +3 more
openaire   +1 more source

Foscarnet/Maribavir

Reactions Weekly
openaire   +1 more source

Letermovir/Maribavir

Reactions Weekly
openaire   +1 more source

Foscarnet/maribavir/valganciclovir

Reactions Weekly, 2019
openaire   +1 more source

Maribavir (Livtencity) for cytomegalovirus infection.

The Medical letter on drugs and therapeutics, 2022
openaire   +1 more source

Foscarnet/ganciclovir/maribavir

Reactions Weekly
openaire   +1 more source